Approximately 70% of all adults in the United States are overweight or have obesity. Unfortunately, obesity remains underdiagnosed and inadequately addressed in routine practice. While enormous strides have been made in recent years relative to the safety and efficacy of anti-obesity medications in inducing meaningful and sustainable weight loss and improvement of weight-related health risks, these agents remain underutilized in clinical practice. To address these gaps and improve the practice of primary care providers (PCPs) who treat patients with obesity, this educational intervention will facilitate exchange of information, clinical experience, and practical guidance, while establishing sustainable support networks between obesity-management specialists and PCPs.
CME/CE Accreditation Information
This dynamic curriculum, detailed by a specialty center clinician, explores each of the CD 19-directed CAR T-cell therapies available for the treatment of DLBCL; solutions to referral and logistic challenges; in-depth early and late toxicity management in CAR T-cell treatment; and the delivery of goal-concordant care using shared decision-making strategies. A challenging real-world case scenario discussion within each Gather-ed group highlights critical decision points, key challenges, and opportunities to incorporate collective insights.
CME/CE Accreditation Information
3.5-credit-hour educational curriculum that brings together 10 groups of 10 professionally connected clinicians led by an expert (called a Group Leader) to comprehensively review key information and best practices to help clinicians formulate their own practice action plans in the care of patients with DLBCL.
CME/CE Accreditation Information
This curriculum focuses on improving outcomes for patients with T2DM who are likely to benefit from the addition of a newer insulin, such as an MTI, to their therapeutic regimen and improving the delivery of telehealth services to underserved patients with T2DM via a multidisciplinary team approach.
CME/CE Accreditation Information
Multiple myeloma is the second-most-common hematologic malignancy in the United States with approximately 34,470 new cases diagnosed in the United States in 2022. Although multiple myeloma is an incurable disease, numerous active agents are available that, when used in combination, often lead to deep and durable remissions however, the majority of patients with multiple myeloma will eventually relapse. As a result, there has been a dramatic increase in the complexity of care for patients with relapsed/refractory multiple myeloma. To address these gaps and improve the practice of clinicians who treat patients with relapsed/refractory multiple myeloma, this educational intervention will facilitate exchange of information, clinical experience, and practical guidance, while establishing sustainable support networks between the multidisciplinary healthcare team.
CME/CE Accreditation Information
